BCL6 overexpression was shown to inhibit oxidative stress responses to chemotherapeutic reagents in B-cell lymphoma cells [43], and BCL6 knockdown increased hypoxia-induced oxidative stress in cardiomyocytes [44]. The gene discussed is BCL6; the disease is B-cell non-Hodgkin lymphoma.